Pluristem Therapeutics Inc., a bio-therapeutics company focused on the commercialization of unrelated donor-patient cell therapy products for a variety of disorders, announced that its Senior Scientist, Racheli Ofir, Ph.D., has been invited by the Centro di Ricerca E. Menni (CREM), Fondazione Poliambulanza, Brescia, Italy, to present at a workshop titled “Placenta-Derived Cells for Treatment of Inflammatory Diseases: Moving Toward Clinical Applications” on March 13, 2009.
Zami Aberman, Chairman, President and CEO of Pluristem, commented, “The research and medical communities are very interested in the placenta as a superior source for cell therapy. This entire workshop is devoted to studies performed on placental cells and their potential for becoming therapeutic products. At Pluristem, we believe the placenta will play a major role in the developing cell therapy market. Based on substantial pre-clinical data, we have developed a pipeline of placental-derived mesenchymal-like stromal cell products, the first one being PLX-PAD for the treatment of critical limb ischemia.”
Let us hear your thoughts below: